144 related articles for article (PubMed ID: 38730732)
1. Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution.
Kawashima A; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Nonomura N
Int J Clin Oncol; 2024 Jun; ():. PubMed ID: 38850448
[TBL] [Abstract][Full Text] [Related]
2. Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
Brown JR; Koshkin VS
Eur Urol Focus; 2024 May; ():. PubMed ID: 38797658
[TBL] [Abstract][Full Text] [Related]
3. Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer.
Strusi A; Pinterpe G; Ciccarese C; Pedone RR; Sarcina M; Sardaro V; Belletto R; Totaro A; Racioppi M; Berardi R; Tortora G; Iacovelli R
Expert Rev Anticancer Ther; 2024 Jun; ():1-4. PubMed ID: 38932631
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Adverse Cutaneous Effects in the Setting of Enfortumab Vedotin for Metastatic Urothelial Carcinoma - a Retrospective Review.
Malik R; Xiang DH; Riew GJ; Sanchez-Melendez S; Afvari S; LeBoeuf NR; Nambudiri VE
J Am Acad Dermatol; 2024 Jun; ():. PubMed ID: 38909660
[No Abstract] [Full Text] [Related]
5. Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?
Nally E; Young M; Wells C; Fairhead R; Baines K; Cheney-Lowe H; Jackson-Spence F; Powles T
Eur Urol Focus; 2024 Jun; ():. PubMed ID: 38825408
[TBL] [Abstract][Full Text] [Related]
6. SDRIFE and bullous reaction after treatment with enfortumab vedotin plus pembrolizumab: Case series.
Lluch-Galcerá JJ; Manzanares-Oliver N; Martinez-Molina M; Valdivieso L; Boada A; Segura S; Rovira R; Pujol RM; Jaka A
J Dtsch Dermatol Ges; 2024 May; ():. PubMed ID: 38778438
[No Abstract] [Full Text] [Related]
7. Toxicities of Novel Agents for the Treatment of Advanced Bladder Cancer.
McInerney S; Jones RJ
Eur Urol Focus; 2024 Jun; ():. PubMed ID: 38851928
[TBL] [Abstract][Full Text] [Related]
8. On the Road Towards Curing Advanced Bladder Cancer.
Szabados B; Powles T
Eur Urol Focus; 2024 Jun; ():. PubMed ID: 38886144
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in urothelial cancer: current status and future directions.
Piombino C; Tonni E; Oltrecolli M; Pirola M; Pipitone S; Baldessari C; Dominici M; Sabbatini R; Vitale MG
Expert Rev Anticancer Ther; 2023; 23(11):1141-1155. PubMed ID: 37772970
[TBL] [Abstract][Full Text] [Related]
10. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
[TBL] [Abstract][Full Text] [Related]
11. How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma.
Larroquette M; Lefort F; Domblides C; Héraudet L; Robert G; Ravaud A; Gross-Goupil M
Cancers (Basel); 2024 May; 16(9):. PubMed ID: 38730732
[TBL] [Abstract][Full Text] [Related]
12. Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin.
Shafique MA; Haseeb A; Siddiq MA; Mussarat A; Rangwala HS; Mustafa MS
Cancer Manag Res; 2023; 15():699-706. PubMed ID: 37485038
[TBL] [Abstract][Full Text] [Related]
13. Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review.
Bantounou MA; Plascevic J; MacDonald L; Wong MC; O'Connell N; Galley HF
Curr Urol; 2023 Dec; 17(4):271-279. PubMed ID: 37994340
[TBL] [Abstract][Full Text] [Related]
14. Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Kawahara T; Hasizume A; Uemura K; Yamaguchi K; Ito H; Takeshima T; Hasumi H; Teranishi JI; Ousaka K; Makiyama K; Uemura H
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686503
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
